{Reference Type}: Case Reports
{Title}: Detection of methaemoglobinaemia in a COVID-19 patient on dapsone.
{Author}: Chagani F;Bansari A;Dass B;
{Journal}: BMJ Case Rep
{Volume}: 17
{Issue}: 1
{Year}: 2024 Jan 9
暂无{DOI}: 10.1136/bcr-2023-256574
{Abstract}: Methaemoglobinaemia occurs when iron in haemoglobin is oxidised into a form that cannot transport oxygen. At low levels, it is asymptomatic, though at rising levels symptoms arise from impaired oxygenation, and it can ultimately be fatal. While uncommon, it is important to consider in hypoxaemic COVID-19 patients, especially if they are not clinically improving on standard treatments and workup for other causes does not explain the ongoing hypoxaemia. It is often diagnosed through a mismatch in peripheral and arterial oxygen, with the former typically less than the latter. We present the case of a COVID-19 patient who was found to have methaemoglobinaemia due to dapsone use for Pneumocystic jirovecii pneumonia (PJP) prophylaxis while on chemotherapy. Dapsone was stopped and supplemental high-flow nasal cannula was provided, and methaemoglobin levels improved over a 5-day period. She was discharged to follow-up with her haematologist in the clinic.